Arvinas, Inc. (NASDAQ:ARVN - Get Free Report) shares shot up 7.4% on Tuesday . The company traded as high as $19.75 and last traded at $19.67. 144,908 shares were traded during mid-day trading, a decline of 84% from the average session volume of 886,925 shares. The stock had previously closed at $18.31.
A number of brokerages have weighed in on ARVN. HC Wainwright reaffirmed a "buy" rating and issued a $87.00 price target on shares of Arvinas in a research note on Wednesday, December 11th. Stephens started coverage on shares of Arvinas in a report on Monday, November 18th. They issued an "overweight" rating and a $55.00 price objective on the stock. Guggenheim restated a "buy" rating and set a $57.00 target price on shares of Arvinas in a report on Wednesday, February 12th. Stifel Nicolaus lowered their target price on shares of Arvinas from $63.00 to $51.00 and set a "buy" rating on the stock in a report on Wednesday, February 12th. Finally, Cantor Fitzgerald reiterated an "overweight" rating on shares of Arvinas in a report on Friday, February 7th. Thirteen research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and an average target price of $60.00.
View Our Latest Report on Arvinas
The company's 50-day moving average is $18.63 and its two-hundred day moving average is $23.05. The firm has a market cap of $1.28 billion, a P/E ratio of -3.99 and a beta of 1.88.
Arvinas (NASDAQ:ARVN - Get Free Report) last posted its quarterly earnings data on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, topping the consensus estimate of ($1.07) by $0.44. During the same quarter in the prior year, the firm posted ($2.53) EPS. On average, analysts expect that Arvinas, Inc. will post -3.22 EPS for the current fiscal year.
Several institutional investors and hedge funds have recently bought and sold shares of ARVN. nVerses Capital LLC bought a new position in shares of Arvinas during the 3rd quarter worth approximately $39,000. KBC Group NV boosted its holdings in shares of Arvinas by 77.0% during the 4th quarter. KBC Group NV now owns 2,885 shares of the company's stock worth $55,000 after buying an additional 1,255 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company's stock worth $61,000 after buying an additional 440 shares in the last quarter. Quantbot Technologies LP boosted its holdings in shares of Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company's stock worth $108,000 after buying an additional 2,601 shares in the last quarter. Finally, Exchange Traded Concepts LLC boosted its holdings in shares of Arvinas by 37.0% during the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company's stock worth $164,000 after buying an additional 1,798 shares in the last quarter. Institutional investors own 95.19% of the company's stock.
Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you make your next trade, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.
Our team has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and none of the big name stocks were on the list.
They believe these five stocks are the five best companies for investors to buy now...
See The Five Stocks Here
Before you consider Arvinas, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Arvinas wasn't on the list.
While Arvinas currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.